Pulmonary Artery Denervation for Pulmonary Hypertension After Mitral Valve Repair
Tests pulmonary artery denervation in adults with pulmonary hypertension after mitral valve repair.
Plain-language title generated from the registry record
Registry title: Percutaneous Pulmonary Artery Denervation (PADN) for the Treatment of Pulmonary Hypertension After Transcatheter Mitral Valve Edge-to-Edge Repair (M-TEER): A Prospective Cohort Study
Key facts
- Where
- Xiamen, ChinaSee the site
- Phase
- Early phase 1
Could this be for you?
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 18 and 80 years old?
Source: NCT07662655, who can take part
Where in China
- Structural Heart Disease Unit, Xiamen Cardiovacular HospitalXiamen, ChinaTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Xiamen Cardiovascular Hospital, Xiamen University
- Trial code
- NCT07662655
- Record updated
- 23 June 2026
- Original description
this study aims to investigate the efficacy and safety of PADN therapy compared with standard medical therapy in patients diagnosed with pulmonary hypertension after M-TEER, thereby providing evidence for clinical treatment decision-makingRead full original descriptionShow less
Percutaneous Pulmonary Artery Denervation (PADN) for the Treatment of Pulmonary Hypertension After Transcatheter Mitral Valve Edge-to-Edge Repair (M-TEER): A Prospective Cohort Study
this study aims to investigate the efficacy and safety of PADN therapy compared with standard medical therapy in patients diagnosed with pulmonary hypertension after M-TEER, thereby providing evidence for clinical treatment decision-making
Inclusion: Age ≥18 years and ≤80 years; Diagnosed with pulmonary hypertension (defined as mPAP >20 mmHg measured by right heart catheterization) at least 3 months after successful M-TEER, having received guideline-directed medical therapy (GDMT) for at least 2 months; No contraindications for PADN (e.g., anatomical abnormalities of the main pulmonary artery precluding catheter placement, known pulmonary artery stenosis, uncontrolled severe arrhythmias); Understands and is willing to sign the informed consent form and authorizes the use of health and study-related information; Willing to comply with the treatment and follow-up schedule required by the protocol.
Exclusion: Anticipated to undergo other surgical or interventional procedures within 6 months; Participation in another drug or medical device clinical trial within 3 months prior to screening; Cardiac index (CI) < 1.5 L/min/m²; Systemic inflammatory disease, malignancy, tricuspid valve stenosis, pulmonary artery stenosis, and other cardiac diseases requiring surgical or interventional treatment; Acute systemic infectious disease; Poor general condition due to various systemic diseases; Pulmonary veno-occlusive disease; Diagnosed with WHO Group 1, 3, 4, or 5 pulmonary hypertension; Allergy to the drugs or metal materials used in the study; Any condition deemed unsuitable for participation in this clinical trial by the investigator. |; Severe renal insufficiency (creatinine clearance rate (CrCL) < 30 mL/min); Left ventricular ejection fraction (EF) <30% on echocardiography; Severe hematological disease or severe bleeding tendency (platelet count <10×10⁹/L; severe and extensive bleeding; suspected or confirmed intracranial hemorrhage); Cachexia; Life expectancy <12 months; Women who are breastfeeding, pregnant, or planning to become pregnant within one year.